A new, fat-dissolving injection for submental fullness (“double chin”) at The Center for Dermatology Care
Submental fullness, sometimes referred to as a “double chin,” is a common but undertreated cosmetic condition. According to a 2014 survey by the American Society for Dermatologic Surgery (ASDS), 68% of consumers are bothered by submental fullness. This cosmetic condition can detract from an otherwise balanced and youthful appearance, leading to a heavier and older look. Until now, treatments were primarily surgical, such as liposuction or facelift surgery.
Kybella™ is a synthetic form of deoxycholic acid and is the first and only FDA-approved injectable drug that improves submental fullness (“double chin”). It is indicated for improvement in the appearance of moderate to severe convexity or fullness in this region. When injected into the submental fat Kybella™ destroys the adipocytes (fat cells). This helps reduce the appearance of the double chin, and once these cells are destroyed they cannot store or accumulate fat again. The treatment is customized by the physician to improve the chin profile, and once the response is achieved (usually over 2-4 treatments), re-treatment is not expected. Seventy-nine percent (79%) of patients treated with Kybella™ reported satisfaction with their appearance in association with their face and chin.
The most commonly reported adverse events with the treatment were injection site swelling, bruising, pain, numbness, redness and firmness. Much less common adverse events included nerve weakness, skin ulceration and difficulty swallowing, most of which resolved by the end of the clinical trials.
Kybella™ is manufactured by Kythera, a Westlake Village company. Dr. Andrew Kaufman is a national speaker on Kybella™ for Kythera and trains other physicians in the proper use of the injection.
For more information or to schedule an appointment with Dr. Kaufman contact The Center for Dermatology Care at (805) 497-1694 or visit our website at www.dermatology-center.com.